Mar 01,2018

Novartis, Pear Therapeutics sign development deal for two digital therapeutics

Pear Therapeutics has inked a deal with pharma company Novartis to work together on the development of two digital therapeutics for multiple sclerosis and schizophrenia. It’s the first time a pharma company has made a development deal with a digital therapeutic, according to Pear. One therapeutic included in the deal, Pear’s Thrive for schizophrenia, has been under development for a while and has already been validated in three clinical trials comprising of more than a thousand patients. The other, a therapeutic designed to address the mental health conditions that come along with multiple sclerosis, will be a new application developed in partnership with Novartis.

COLLABORATION PARTNERSHIP

#r&d

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jul 05,2022

Biogen leans into digital therapeutics for multiple sclerosis, teams with Happify Health

Biogen and Happify Health today announced a collaboration to provide a digital solution for patient education and engagement, powered by artificial intelligence (AI), to support people living with multiple sclerosis (MS). Biogen’s interest is in reaching the MS patients on the platform who may be interested in information on new treatments, and the company will provide support for the MS platform, including educational content and resources for the patient care journey. Biogen’s portfolio of MS drugs includes Tecfidera, Vumerity and Tysabri. In addition to psoriasis and maternal health, MS is the third therapeutic area to be addressed through Happify Health's unique Sequence approach. 

COLLABORATION PARTNERSHIP

#r&d

#mobile app

View Analyst & Ambassador Comments
Go to original news
Subscribe to MS